» Articles » PMID: 7786985

Evaluation of Experiments with Adaptive Interim Analyses

Overview
Journal Biometrics
Specialty Public Health
Date 1994 Dec 1
PMID 7786985
Citations 126
Authors
Affiliations
Soon will be listed here.
Abstract

A general method for statistical testing in experiments with an adaptive interim analysis is proposed. The method is based on the observed error probabilities from the disjoint subsamples before and after the interim analysis. Formally, an intersection of individual null hypotheses is tested by combining the two p-values into a global test statistic. Stopping rules for Fisher's product criterion in terms of critical limits for the p-value in the first subsample are introduced, including early stopping in the case of missing effects. The control of qualitative treatment-stage interactions is considered. A generalization to three stages is outlined. The loss of power when using the product criterion instead of the optimal classical test on the whole sample is calculated for the test of the mean of a normal distribution, depending on increasing proportions of the first subsample in relation to the total sample size. An upper bound on the loss of power due to early stopping is derived. A general example is presented and rules for assessing the sample size in the second stage of the trial are given. The problems of interpretation and precautions to be taken for applications are discussed. Finally, the sources of bias for estimation in such designs are described.

Citing Articles

The assessment of replicability using the sum of -values.

Held L, Pawel S, Micheloud C R Soc Open Sci. 2024; 11(8):240149.

PMID: 39205991 PMC: 11349439. DOI: 10.1098/rsos.240149.


The impact of heterogeneity on the analysis of platform trials with normally distributed outcomes.

Lee K, Emsley R BMC Med Res Methodol. 2024; 24(1):163.

PMID: 39080538 PMC: 11290279. DOI: 10.1186/s12874-024-02293-4.


Efficient testing of the biomarker positive and negative subgroups in a biomarker-stratified trial.

Li L, Ivanova A Biometrics. 2024; 80(2).

PMID: 38861372 PMC: 11166030. DOI: 10.1093/biomtc/ujae056.


RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial.

Holubovska O, Babich P, Mironenko A, Milde J, Lebed Y, Stammer H Adv Respir Med. 2024; 92(3):202-217.

PMID: 38804439 PMC: 11130936. DOI: 10.3390/arm92030021.


A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison.

Zang Y, Thall P, Yuan Y Biometrics. 2024; 80(1).

PMID: 38364811 PMC: 10873567. DOI: 10.1093/biomtc/ujad022.